Related Experiment Video

Updated: Apr 7, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?

Shuai Wang1, Zhe Yang2, Zhou Wang1

  • 1Department of Thoracic Surgery, Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, People's Republic of China.

Oncotarget
|July 10, 2015
PubMed

Insights

Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) improve progression-free survival and response rates in advanced non-small cell lung cancer (NSCLC). However, these therapies increase adverse events without significantly impacting overall survival.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Advanced non-small cell lung cancer (NSCLC) presents significant therapeutic challenges.
  • Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) have emerged as potential targeted therapies.

Purpose of the Study:

  • To quantitatively evaluate the efficacy and safety of VEGFR-TKIs in advanced NSCLC patients.
  • To compare outcomes of VEGFR-TKIs regimens versus non-VEGFR-TKIs.

Main Methods:

  • Meta-analysis of 23 randomized controlled trials (RCTs).
  • Inclusion of 12,520 patients with advanced NSCLC.
  • Quantitative assessment of progression-free survival (PFS), objective response rates (ORR), disease control rates (DCR), overall survival (OS), and adverse events (AEs).

Main Results:

  • VEGFR-TKIs significantly improved PFS, ORR, and DCR compared to non-VEGFR-TKIs.
  • No significant improvement in overall survival (OS) was observed with VEGFR-TKIs.
  • Increased incidence of all-grade and high-grade adverse events, including neutropenia, thrombocytopenia, hypertension, and rash, was associated with VEGFR-TKIs.

Conclusions:

  • VEGFR-TKIs demonstrate efficacy in improving PFS, ORR, and DCR for advanced NSCLC.
  • The use of VEGFR-TKIs is associated with a higher risk of both mild and severe adverse events.
  • VEGFR-TKIs do not significantly improve overall survival in advanced NSCLC patients, necessitating careful risk-benefit assessment.
Keywords:
TKIsVEGFRangiogenesis inhibitorslung cancermeta analysis

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
654
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
566